The superiority of insulin degludec vs. glargine in terms of hypoglycaemic risk has been widely demonstrated in patients both with T1D (SWITCH 1) (19) and with T2D (SWITCH 2) (18, 20). The gene discussed is INS; the disease is type 1 diabetes mellitus.